跳至主要内容
临床试验/EUCTR2006-003682-14-DE
EUCTR2006-003682-14-DE进行中(未招募)不适用

Randomised phase II study on the treatment with pegfilgrastim after autologous blood stem cell transplantation

GMIHO Gesellschaft für Medizinische Innovation/Hämatologie und Onkologie mbH0 个研究点开始时间: 2007年2月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - patients with leukemia (with exceptions, cf. exclusion criteria), lymphoma or multiple myeloma (first-line or in first relapse) after autologous peripheral blood stem cell transplantation
  • - transfused CD34+ >= 2,0*10^6/kg body weight
  • - age >= 18 years
  • - adequate contraceptive measures in case of reproductive potential (oral contraceptives, implantable or injectable contraceptive drugs, hormonal IUDs, vasectomy of the partner, or abstinence
  • - negative pregnancy test
  • - written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - hypersensitivity against pegfilgrastim, other proteins manufactured using E. coli, or one of the drugs other components
  • - patients with myelodysplastic syndrome
  • - patients with chronic myeloid leukemia
  • - patients with secondary AML
  • - pregnant or lactating women
  • - insufficient compliance anticipated

研究者

发起方
GMIHO Gesellschaft für Medizinische Innovation/Hämatologie und Onkologie mbH

相似试验